# Patent

## Title
Organic electroluminescent materials and devices

## Abstract

This invention discloses novel metal complexes for phosphorescent OLEDs. The incorporation of a specific nitrogen substitution in the benzimidazole phenanthridine ligand system is shown to provide desirable color.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority from U.S. Provisional Patent Application Ser. Nos. 61/979,103, filed Apr. 14, 2014, and 61/991,720, filed May 12, 2014, the entire contents of each of which is incorporated herein by reference.


PARTIES TO A JOINT RESEARCH AGREEMENT
The claimed invention was made by, on behalf of, and/or in connection with one or more of the following parties to a joint university corporation research agreement: Regents of the University of Michigan, Princeton University, University of Southern California, and the Universal Display Corporation. The agreement was in effect on and before the date the claimed invention was made, and the claimed invention was made as a result of activities undertaken within the scope of the agreement.
FIELD OF THE INVENTION
The present invention relates to compounds for use as emitters and devices, such as organic light emitting diodes, including the same.
BACKGROUND
Opto-electronic devices that make use of organic materials are becoming increasingly desirable for a number of reasons. Many of the materials used to make such devices are relatively inexpensive, so organic opto-electronic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials, such as their flexibility, may make them well suited for particular applications such as fabrication on a flexible substrate. Examples of organic opto-electronic devices include organic light emitting devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, the organic materials may have performance advantages over conventional materials. For example, the wavelength at which an organic emissive layer emits light may generally be readily tuned with appropriate dopants.
OLEDs make use of thin organic films that emit light when voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for use in applications such as flat panel displays, illumination, and backlighting. Several OLED materials and configurations are described in U.S. Pat. Nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.
One application for phosphorescent emissive molecules is a full color display. Industry standards for such a display call for pixels adapted to emit particular colors, referred to as “saturated” colors. In particular, these standards call for saturated red, green, and blue pixels. Color may be measured using CIE coordinates, which are well known to the art.
One example of a green emissive molecule is tris(2-phenylpyridine) iridium, denoted Ir(ppy)3, which has the following structure:




In this, and later figures herein, we depict the dative bond from nitrogen to metal (here, Ir) as a straight line.
As used herein, the term “organic” includes polymeric materials as well as small molecule organic materials that may be used to fabricate organic opto-electronic devices. “Small molecule” refers to any organic material that is not a polymer, and “small molecules” may actually be quite large. Small molecules may include repeat units in some circumstances. For example, using a long chain alkyl group as a substituent does not remove a molecule from the “small molecule” class. Small molecules may also be incorporated into polymers, for example as a pendent group on a polymer backbone or as a part of the backbone. Small molecules may also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of a dendrimer may be a fluorescent or phosphorescent small molecule emitter. A dendrimer may be a “small molecule,” and it is believed that all dendrimers currently used in the field of OLEDs are small molecules.
As used herein, “top” means furthest away from the substrate, while “bottom” means closest to the substrate. Where a first layer is described as “disposed over” a second layer, the first layer is disposed further away from substrate. There may be other layers between the first and second layer, unless it is specified that the first layer is “in contact with” the second layer. For example, a cathode may be described as “disposed over” an anode, even though there are various organic layers in between.
As used herein, “solution processible” means capable of being dissolved, dispersed, or transported in and/or deposited from a liquid medium, either in solution or suspension form.
A ligand may be referred to as “photoactive” when it is believed that the ligand directly contributes to the photoactive properties of an emissive material. A ligand may be referred to as “ancillary” when it is believed that the ligand does not contribute to the photoactive properties of an emissive material, although an ancillary ligand may alter the properties of a photoactive ligand.
As used herein, and as would be generally understood by one skilled in the art, a first “Highest Occupied Molecular Orbital” (HOMO) or “Lowest Unoccupied Molecular Orbital” (LUMO) energy level is “greater than” or “higher than” a second HOMO or LUMO energy level if the first energy level is closer to the vacuum energy level. Since ionization potentials (IP) are measured as a negative energy relative to a vacuum level, a higher HOMO energy level corresponds to an IP having a smaller absolute value (an IP that is less negative). Similarly, a higher LUMO energy level corresponds to an electron affinity (EA) having a smaller absolute value (an EA that is less negative). On a conventional energy level diagram, with the vacuum level at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. A “higher” HOMO or LUMO energy level appears closer to the top of such a diagram than a “lower” HOMO or LUMO energy level.
As used herein, and as would be generally understood by one skilled in the art, a first work function is “greater than” or “higher than” a second work function if the first work function has a higher absolute value. Because work functions are generally measured as negative numbers relative to vacuum level, this means that a “higher” work function is more negative. On a conventional energy level diagram, with the vacuum level at the top, a “higher” work function is illustrated as further away from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different convention than work functions.
More details on OLEDs, and the definitions described above, can be found in U.S. Pat. No. 7,279,704, which is incorporated herein by reference in its entirety.
Substitution of nitrogen in a specific position in the polycyclic benzimidazole phenanthridine ligand system can lead to a profound blue shifting effect. However, the uncoordinated nitrogen presents a stability issue as it may be susceptible to protonation in the excited state. There is a need in the art to prevent protonation of the uncoordinated nitrogen in the polycyclic benzimidazole phenanthridine ligand system while maintaining the blue shifting effect. The present invention addresses this unmet need.
SUMMARY OF THE INVENTION
According to an embodiment, a compound is provided that comprises a ligand LA of Formula I:




wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.
In one embodiment, the compound has the formula M(LA)m(LB)n, having the structure:




wherein LB is a different ligand from LA; and
wherein m is an integer from 1 to the maximum number of ligands that may be coordinated to the metal M; m+n is the maximum number of ligands that may be coordinated to the metal M.
In one embodiment, M is selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu. In another embodiment, M is Ir.
In one embodiment, the ligand LA has the structure of:




wherein R is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one embodiment, R is selected from the group consisting of alkyl, cycloalkyl, silyl, aryl, heteroaryl, and combinations thereof. In one embodiment, R is selected from the group consisting of methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, phenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 4-isobutylphenyl, and combinations thereof.
In one embodiment, the compound has the structure:




In one embodiment, the compound has the structure:




In one embodiment, the ligand LA is selected from the group consisting of LA1 through LA316.
In one embodiment, the compound is selected from the group consisting of Compound 1 through Compound 316; wherein each Compound x has the formula Ir(LAi)3; and wherein x=i; i is an integer from 1 to 316.
In one embodiment, the compound has the formula Ir(LA)m(LB)3-m, having the structure:




wherein LB is a different ligand from LA;
wherein m is 1 or 2;
wherein LB is selected from the group consisting of:










wherein each X1 to X13 is independently selected from the group consisting of carbon and nitrogen;
wherein X is selected from the group consisting of BR′, NR′, PR′, O, S, Se, C═O, S═O, SO2, CR′R′′, SiR′R′′, and GeR′R′′;
wherein R′ and R′′ are optionally fused or joined to form a ring;
wherein each Ra, Rb, Rc, and Rd may represent from mono substitution to the possible maximum number of substitution, or no substitution;
wherein Ra, Rb, Rc, and Rd are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; and
wherein when Ra, Rb, Rc, and Rd represent at least di substitution, each of the two adjacent Ra, two adjacent Rb, two adjacent Rc, and two adjacent Rd are optionally fused or joined to form a ring or form a multidentate ligand.
In one embodiment, LB is selected from the group consisting of LB1 through LB267.
In one embodiment, the compound is selected from the group consisting of Compound 317 through Compound 84,688; wherein each Compound x has the formula Ir(LAi)(LBj)2;
wherein LBi is selected from the group consisting of LB1 through LB267; and
wherein x=316j+i; i is an integer from 1 to 316, and j is an integer from 1 to 267.
In one embodiment, the LB is chosen such that the HOMO energy in Ir(LB)3 is deeper than that in Ir(LA)3.
In one embodiment, the compound is selected from the group consisting of:













According to another embodiment, a first device comprising a first organic light emitting device is also provided. The first organic light emitting device can include an anode, a cathode, and an organic layer, disposed between the anode and the cathode. The organic layer can include a compound of Formula I. The first device can be a consumer product, an organic light-emitting device, and/or a lighting panel.
In one embodiment, the first device comprises a first organic light emitting device, the first organic light emitting device comprising:
an anode;
a cathode; and
an organic layer, disposed between the anode and the cathode, comprising a compound comprising a ligand LA of Formula I:




wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.
In one embodiment, the first device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel. In another embodiment, the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant. In another embodiment, the organic layer is a charge transporting layer and the compound is a charge transporting material in the organic layer. In another embodiment, the organic layer is a blocking layer and the compound is a blocking material in the organic layer.
In one embodiment, the organic layer further comprises a host; wherein the host comprises a triphenylene containing benzo-fused thiophene or benzo-fused furan;
wherein any substituent in the host is an unfused substituent independently selected from the group consisting of CnH2n+1, OCnH2n+1, OAr1, N(CnH2n+1)2, N(Ar1)(Ar2), CH═CH—CnH2n+1, C≡CCnH2n+1, Ar1, Ar1—Ar2, CnH2nAr1, or no substitution;
wherein n is from 1 to 10; and
wherein Ar1 and Ar2 are independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
In one embodiment, the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.
In one embodiment, the organic layer further comprises a host and the host is selected from the group consisting of:
















and combinations thereof.

In one embodiment, the organic layer further comprises a host and the host comprises a metal complex.
According to another embodiment, a formulation comprising the above compound is also provided. In one embodiment, the formulation comprises a compound comprising a ligand LA of Formula I:




wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows an organic light emitting device.
FIG. 2 shows an inverted organic light emitting device that does not have a separate electron transport layer.
FIG. 3 shows spectral data for Comparative Example 1 at room temperature and at 77K in 2-methyltetrahydrofuran solvent.
FIG. 4 shows a minimized space filling model of Compound 315. The uncoordinated nitrogen atom is completely shielded by the plane of the phenyl substituent. Two of the ligands have been hidden for clarity.
FIG. 5 shows spectral data for Comparative Example 3 at 77K in 2-methyltetrahydrofuran as solvent.
FIG. 6 shows an emission spectrum of Compound 7 in room temperature and a 77K emission spectrum in 2-methyl THF solvent and PMMA matrix.
FIG. 7 shows an exemplary synthetic scheme of Compounds 306-308.
FIG. 8 shows an exemplary synthetic scheme of Compounds 110, 309, and 310.
FIG. 9 shows an exemplary synthetic scheme of Compound 311.
FIG. 10 shows an exemplary synthetic scheme of Compound 4.
FIG. 11 shows an exemplary synthetic scheme of Compound 7.
FIG. 12 shows an exemplary synthetic scheme of Compounds 312-314.



DETAILED DESCRIPTION
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When a current is applied, the anode injects holes and the cathode injects electrons into the organic layer(s). The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and hole localize on the same molecule, an “exciton,” which is a localized electron-hole pair having an excited energy state, is formed. Light is emitted when the exciton relaxes via a photoemissive mechanism. In some cases, the exciton may be localized on an excimer or an exciplex. Non-radiative mechanisms, such as thermal relaxation, may also occur, but are generally considered undesirable.
The initial OLEDs used emissive molecules that emitted light from their singlet states (“fluorescence”) as disclosed, for example, in U.S. Pat. No. 4,769,292, which is incorporated by reference in its entirety. Fluorescent emission generally occurs in a time frame of less than 10 nanoseconds.
More recently, OLEDs having emissive materials that emit light from triplet states (“phosphorescence”) have been demonstrated. Baldo et al., “Highly Efficient Phosphorescent Emission from Organic Electroluminescent Devices,” Nature, vol. 395, 151-154, 1998; (“Baldo-I”) and Baldo et al., “Very high-efficiency green organic light-emitting devices based on electrophosphorescence,” Appl. Phys. Lett., vol. 75, No. 3, 4-6 (1999) (“Baldo-II”), which are incorporated by reference in their entireties. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704 which is incorporated by reference in its entirety.
FIG. 1 shows an organic light emitting device 100. The figures are not necessarily drawn to scale. Device 100 may include a substrate 110, an anode 115, a hole injection layer 120, a hole transport layer 125, an electron blocking layer 130, an emissive layer 135, a hole blocking layer 140, an electron transport layer 145, an electron injection layer 150, a protective layer 155, a cathode 160, and a barrier layer 170. Cathode 160 is a compound cathode having a first conductive layer 162 and a second conductive layer 164. Device 100 may be fabricated by depositing the layers described, in order. The properties and functions of these various layers, as well as example materials, are described in more detail in U.S. Pat. No. 7,279,704 which is incorporated by reference in its entirety.
More examples for each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is m-MTDATA doped with F4-TCNQ at a molar ratio of 50:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of emissive and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al., which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entireties, disclose examples of cathodes including compound cathodes having a thin layer of metal such as Mg:Ag with an overlying transparent, electrically-conductive, sputter-deposited ITO layer. The theory and use of blocking layers is described in more detail in U.S. Pat. No. 6,097,147 and U.S. Patent Application Publication No. 2003/0230980, which are incorporated by reference in their entireties. Examples of injection layers are provided in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of protective layers may be found in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety.
FIG. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. Device 200 may be fabricated by depositing the layers described, in order. Because the most common OLED configuration has a cathode disposed over the anode, and device 200 has cathode 215 disposed under anode 230, device 200 may be referred to as an “inverted” OLED. Materials similar to those described with respect to device 100 may be used in the corresponding layers of device 200. FIG. 2 provides one example of how some layers may be omitted from the structure of device 100.
The simple layered structure illustrated in FIGS. 1 and 2 is provided by way of non-limiting example, and it is understood that embodiments of the invention may be used in connection with a wide variety of other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be achieved by combining the various layers described in different ways, or layers may be omitted entirely, based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe various layers as comprising a single material, it is understood that combinations of materials, such as a mixture of host and dopant, or more generally a mixture, may be used. Also, the layers may have various sublayers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an “organic layer” disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to FIGS. 1 and 2.
Structures and materials not specifically described may also be used, such as OLEDs comprised of polymeric materials (PLEDs) such as disclosed in U.S. Pat. No. 5,247,190 to Friend et al., which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. OLEDs may be stacked, for example as described in U.S. Pat. No. 5,707,745 to Forrest et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in FIGS. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling, such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Forrest et al., and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Bulovic et al., which are incorporated by reference in their entireties.
Unless otherwise specified, any of the layers of the various embodiments may be deposited by any suitable method. For the organic layers, preferred methods include thermal evaporation, ink-jet, such as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, which are incorporated by reference in their entireties, organic vapor phase deposition (OVPD), such as described in U.S. Pat. No. 6,337,102 to Forrest et al., which is incorporated by reference in its entirety, and deposition by organic vapor jet printing (OVJP), such as described in U.S. Pat. No. 7,431,968, which is incorporated by reference in its entirety. Other suitable deposition methods include spin coating and other solution based processes. Solution based processes are preferably carried out in nitrogen or an inert atmosphere. For the other layers, preferred methods include thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding such as described in U.S. Pat. Nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entireties, and patterning associated with some of the deposition methods such as ink jet and OVJD. Other methods may also be used. The materials to be deposited may be modified to make them compatible with a particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3-20 carbons is a preferred range. Materials with asymmetric structures may have better solution processibility than those having symmetric structures, because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated in accordance with embodiments of the present invention may further optionally comprise a barrier layer. One purpose of the barrier layer is to protect the electrodes and organic layers from damaging exposure to harmful species in the environment including moisture, vapor and/or gases, etc. The barrier layer may be deposited over, under or next to a substrate, an electrode, or over any other parts of a device including an edge. The barrier layer may comprise a single layer, or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase as well as compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic or an organic compound or both. The preferred barrier layer comprises a mixture of a polymeric material and a non-polymeric material as described in U.S. Pat. No. 7,968,146, PCT Pat. Application Nos. PCT/US2007/023098 and PCT/US2009/042829, which are herein incorporated by reference in their entireties. To be considered a “mixture”, the aforesaid polymeric and non-polymeric materials comprising the barrier layer should be deposited under the same reaction conditions and/or at the same time. The weight ratio of polymeric to non-polymeric material may be in the range of 95:5 to 5:95. The polymeric material and the non-polymeric material may be created from the same precursor material. In one example, the mixture of a polymeric material and a non-polymeric material consists essentially of polymeric silicon and inorganic silicon.
Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of electronic component modules (or units) that can be incorporated into a variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices such as discrete light source devices or lighting panels, etc. that can be utilized by the end-user product manufacturers. Such electronic component modules can optionally include the driving electronics and/or power source(s). Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of consumer products that have one or more of the electronic component modules (or units) incorporated therein. Such consumer products would include any kind of products that include one or more light source(s) and/or one or more of some type of visual displays. Some examples of such consumer products include flat panel displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, laser printers, telephones, cell phones, tablets, phablets, personal digital assistants (PDAs), laptop computers, digital cameras, camcorders, viewfinders, micro-displays, 3-D displays, vehicles, a large area wall, theater or stadium screen, or a sign. Various control mechanisms may be used to control devices fabricated in accordance with the present invention, including passive matrix and active matrix. Many of the devices are intended for use in a temperature range comfortable to humans, such as 18 degrees C. to 30 degrees C., and more preferably at room temperature (20-25 degrees C.), but could be used outside this temperature range, for example, from −40 degree C. to +80 degree C.
The materials and structures described herein may have applications in devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices, such as organic transistors, may employ the materials and structures.
The term “halo,” “halogen,” or “halide” as used herein includes fluorine, chlorine, bromine, and iodine.
The term “alkyl” as used herein contemplates both straight and branched chain alkyl radicals. Preferred alkyl groups are those containing from one to fifteen carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like. Additionally, the alkyl group may be optionally substituted.
The term “cycloalkyl” as used herein contemplates cyclic alkyl radicals. Preferred cycloalkyl groups are those containing 3 to 7 carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, and the like. Additionally, the cycloalkyl group may be optionally substituted.
The term “alkenyl” as used herein contemplates both straight and branched chain alkene radicals. Preferred alkenyl groups are those containing two to fifteen carbon atoms. Additionally, the alkenyl group may be optionally substituted.
The term “alkynyl” as used herein contemplates both straight and branched chain alkyne radicals. Preferred alkynyl groups are those containing two to fifteen carbon atoms. Additionally, the alkynyl group may be optionally substituted.
The terms “aralkyl” or “arylalkyl” as used herein are used interchangeably and contemplate an alkyl group that has as a substituent an aromatic group. Additionally, the aralkyl group may be optionally substituted.
The term “heterocyclic group” as used herein contemplates aromatic and non-aromatic cyclic radicals. Hetero-aromatic cyclic radicals also means heteroaryl. Preferred hetero-non-aromatic cyclic groups are those containing 3 or 7 ring atoms which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperdino, pyrrolidino, and the like, and cyclic ethers, such as tetrahydrofuran, tetrahydropyran, and the like. Additionally, the heterocyclic group may be optionally substituted.
The term “aryl” or “aromatic group” as used herein contemplates single-ring groups and polycyclic ring systems. The polycyclic rings may have two or more rings in which two carbons are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the aryl group may be optionally substituted.
The term “heteroaryl” as used herein contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine and pyrimidine, and the like. The term heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the heteroaryl group may be optionally substituted.
The alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heterocyclic group, aryl, and heteroaryl may be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, cyclic amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
As used herein, “substituted” indicates that a substituent other than H is bonded to the relevant position, such as carbon. Thus, for example, where R1 is mono-substituted, then one R1 must be other than H. Similarly, where R1 is di-substituted, then two of R1 must be other than H. Similarly, where R1 is unsubstituted, R1 is hydrogen for all available positions.
The “aza” designation in the fragments described herein, i.e. aza-dibenzofuran, aza-dibenzothiophene, etc. means that one or more of the C—H groups in the respective fragment can be replaced by a nitrogen atom, for example, and without any limitation, azatriphenylene encompasses both dibenzo[f,h]quinoxaline and dibenzo[f,h]quinoline. One of ordinary skill in the art can readily envision other nitrogen analogs of the aza-derivatives described above, and all such analogs are intended to be encompassed by the terms as set forth herein.
It is to be understood that when a molecular fragment is described as being a substituent or otherwise attached to another moiety, its name may be written as if it were a fragment (e.g. phenyl, phenylene, naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g. benzene, naphthalene, dibenzofuran). As used herein, these different ways of designating a substituent or attached fragment are considered to be equivalent.
Substitution of nitrogen in a specific position in the polycyclic benzimidazole phenanthridine ligand system can lead to a profound blue shifting effect. However, the uncoordinated nitrogen presents a stability issue as it may be susceptible to protonation in the excited state. The three ring structure of benzimidazole phenanthridine has a site that, when substituted with a bulky group, such as an aryl ring, shields the uncoordinated nitrogen from the protons of neighboring molecules. Therefore, this type of substitution in this position is useful for improving stability by preventing the uncoordinated nitrogen from being protonated. In addition, substituting a conjugating aryl ring at this position requires that the ring is fully twisted out of plane; therefore, aryl substitution at this site does not lower the triplet energy of the complex.
Compounds of the Invention:
The compounds of the present invention may be synthesized using techniques well-known in the art of organic synthesis. The starting materials and intermediates required for the synthesis may be obtained from commercial sources or synthesized according to methods known to those skilled in the art.
In one aspect, the compound of the invention is a compound comprising a ligand LA of Formula I:




wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.
The metal M is not particularly limited. Examples of metals useful in the compounds of the present invention include, but are not limited to, transition metals such as Ir, Pt, Au, Re, Ru, W, Rh, Ru, Os, Pd, Ag, Cu, Co, Zn, Ni, Pb, Al, and Ga. In one embodiment, M is selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu. In another embodiment, M is Ir.
In one embodiment, the ligand LA has the structure of:




wherein R is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.

In one embodiment, R is selected from the group consisting of alkyl, cycloalkyl, silyl, aryl, heteroaryl, and combinations thereof. In another embodiment, R is selected from the group consisting of methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, phenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 4-isobutylphenyl, and combinations thereof.
In one embodiment, the ligand LA is selected from the group consisting of:





































































































































































































































In some embodiments, the compound comprises two or more ligands LA, wherein the two or more ligands LA are the same ligands. In other embodiments, the compound comprises two or more ligands LA, wherein at least one of the ligands LA is a different ligand from the other ligands LA. In some embodiments, the compound comprises at least one ligand LA and at least one ligand LB, wherein LB is a different ligand from LA. LB is not particularly limited. In one embodiment, LB is a bidentate ligand. Additionally, ligands LB may be optionally substituted, and any adjacent substituents may be optionally fused or joined to form a ring or form a multidentate ligand. In one embodiment, the LB is chosen such that the HOMO energy in Ir(LB)3 is deeper than that in Ir(LA)3.
In one embodiment, LB is selected from the group consisting of:










wherein each X1 to X13 are independently selected from the group consisting of carbon and nitrogen;
wherein X is selected from the group consisting of BR′, NR′, PR′, O, S, Se, C═O, S═O, SO2, CR′R′′, SiR′R′′, and GeR′R′′;
wherein R′ and R′′ are optionally fused or joined to form a ring;
wherein each Ra, Rb, Rc, and Rd may represent from mono substitution to the possible maximum number of substitution, or no substitution;
wherein Ra, Rb, Rc, and Rd are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; and
wherein when Ra, Rb, Rc, and Rd represent at least di substitution, each of the two adjacent Ra, two adjacent Rb, two adjacent Rc, and two adjacent Rd are optionally fused or joined to form a ring or form a multidentate ligand.
In one embodiment, LB is selected from the group consisting of:
























































































































































































In one embodiment, the compound has the formula M(LA)m(LB)n, having the structure:




wherein LB is a different ligand from LA; and
wherein m is an integer from 1 to the maximum number of ligands that may be coordinated to the metal M; m+n is the maximum number of ligands that may be coordinated to the metal M.
In one embodiment, the compound is selected from the group consisting of Compound 1 through Compound 316; wherein each Compound x has the formula Ir(LAi)3, and wherein x=i; i is an integer from 1 to 316. For example, if the compound has the formula Ir(LA35)3, the compound is Compound 35. In another embodiment, the compound is selected from the group consisting of Compound 317 through Compound 84,688, wherein each Compound x has the formula Ir(LAi)(LBj)2, and wherein x=316j+i; i is an integer from 1 to 316, and j is an integer from 1 to 267. For example, if the compound has formula Ir(LA35)(LB15)2, the compound is Compound 4,775. In another embodiment, the compound is selected from the group consisting of Compound 84,689 through Compound 169,060, wherein each Compound x has the formula Ir(LAi)2(LBj), and wherein x=84,372+316j+i; i is an integer from 1 to 316, and j is an integer from 1 to 267. In one embodiment, ligand LAi is at least one ligand LA. In one embodiment, ligand LBj is at least one ligand LB.
In one embodiment, the compound has the structure:




In one embodiment, the compound has the structure:




In one embodiment, the compound is selected from the group consisting of:
















In some embodiments, the compound can be an emissive dopant. In some embodiments, the compound can produce emissions via phosphorescence, fluorescence, thermally activated delayed fluorescence, i.e., TADF (also referred to as E-type delayed fluorescence), triplet-triplet annihilation, or combinations of these processes.
Devices:
According to another aspect of the present disclosure, a first device is also provided. The first device includes a first organic light emitting device, that includes an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer may include a host and a phosphorescent dopant. The emissive layer can include a compound according to Formula I, and its variations as described herein.
The first device can be one or more of a consumer product, an electronic component module, an organic light-emitting device and a lighting panel. The organic layer can be an emissive layer and the compound can be an emissive dopant in some embodiments, while the compound can be a non-emissive dopant in other embodiments. The organic layer can be a charge transporting layer and the compound can be a charge transporting material in the organic layer in some embodiments. The organic layer can be a blocking layer and the compound can be a blocking material in the organic layer in some embodiments.
The organic layer can also include a host. In some embodiments, the host can include a metal complex. The host can be a triphenylene containing benzo-fused thiophene or benzo-fused furan. Any substituent in the host can be an unfused substituent independently selected from the group consisting of CnH2n+1, OCnH2n+1, OAr1, N(CnH2n+1)2, N(Ar1)(Ar2), CH═CH—CnH2n+1, C≡C—CnH2n+1, Ar1, Ar1—Ar2, and CnH2nAr1, or no substitution. In the preceding substituents n can range from 1 to 10; and Ar1 and Ar2 can be independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
The host can be a compound comprising at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene. The host can include a metal complex. The host can be a specific compound selected from the group consisting of:
















and combinations thereof.

Formulations:

In yet another aspect of the present disclosure, a formulation that comprises a compound according to Formula I is described. The formulation can include one or more components selected from the group consisting of a solvent, a host, a hole injection material, hole transport material, and an electron transport layer material, disclosed herein.
Combination with Other Materials
The materials described herein as useful for a particular layer in an organic light emitting device may be used in combination with a wide variety of other materials present in the device. For example, emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, blocking layers, injection layers, electrodes and other layers that may be present. The materials described or referred to below are non-limiting examples of materials that may be useful in combination with the compounds disclosed herein, and one of skill in the art can readily consult the literature to identify other materials that may be useful in combination.
HIL/HTL:
A hole injecting/transporting material to be used in the present invention is not particularly limited, and any compound may be used as long as the compound is typically used as a hole injecting/transporting material. Examples of the material include, but are not limited to: a phthalocyanine or porphyrin derivative; an aromatic amine derivative; an indolocarbazole derivative; a polymer containing fluorohydrocarbon; a polymer with conductivity dopants; a conducting polymer, such as PEDOT/PSS; a self-assembly monomer derived from compounds such as phosphonic acid and silane derivatives; a metal oxide derivative, such as MoOx; a p-type semiconducting organic compound, such as 1,4,5,8,9,12-Hexaazatriphenylenehexacarbonitrile; a metal complex, and cross-linkable compounds.
Examples of aromatic amine derivatives used in HIL or HTL include, but are not limited to the following general structures:




Each of Ar1 to Ar9 is selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each Ar is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, Ar1 to Ar9 is independently selected from the group consisting of:




wherein k is an integer from 1 to 20; X101 to X108 is C (including CH) or N; Z101 is NAr1, O, or S; Ar1 has the same group defined above.

Examples of metal complexes used in HIL or HTL include, but are not limited to the following general formula:




wherein Met is a metal, which can have an atomic weight greater than 40; (Y101-Y102) is a bidentate ligand, Y101 and Y102 are independently selected from C, N, O, P, and S; L101 is an ancillary ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k′′ is the maximum number of ligands that may be attached to the metal.

In one aspect, (Y101-Y102) is a 2-phenylpyridine derivative. In another aspect, (Y101-Y102) is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os, and Zn. In a further aspect, the metal complex has a smallest oxidation potential in solution vs. Fc+/Fc couple less than about 0.6 V.
Host:
The light emitting layer of the organic EL device of the present invention preferably contains at least a metal complex as light emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complexes or organic compounds may be used as long as the triplet energy of the host is larger than that of the dopant. While the Table below categorizes host materials as preferred for devices that emit various colors, any host material may be used with any dopant so long as the triplet criteria is satisfied.
Examples of metal complexes used as host are preferred to have the following general formula:




wherein Met is a metal; (Y103-Y104) is a bidentate ligand, Y103 and Y104 are independently selected from C, N, O, P, and S; L101 is an another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k′′ is the maximum number of ligands that may be attached to the metal.

In one aspect, the metal complexes are:




wherein (O—N) is a bidentate ligand, having metal coordinated to atoms O and N.

In another aspect, Met is selected from Ir and Pt. In a further aspect, (Y103-Y104) is a carbene ligand.
Examples of organic compounds used as host are selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each group is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, the host compound contains at least one of the following groups in the molecule:







wherein R101 to R107 is independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. k is an integer from 0 to 20 or 1 to 20; k′′′ is an integer from 0 to 20. X101 to X108 is selected from C (including CH) or N. Z101 and Z102 is selected from NR101, O, or S.

HBL:

A hole blocking layer (HBL) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a blocking layer in a device may result in substantially higher efficiencies as compared to a similar device lacking a blocking layer. Also, a blocking layer may be used to confine emission to a desired region of an OLED.
In one aspect, the compound used in the HBL contains the same molecule or the same functional groups used as the host described above.
In another aspect, the compound used in the HBL contains at least one of the following groups in the molecule:




wherein k is an integer from 1 to 20; L101 is an another ligand, k′ is an integer from 1 to 3.

ETL:

Electron transport layer (ETL) may include a material capable of transporting electrons. Electron transport layer may be intrinsic (undoped), or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complexes or organic compounds may be used as long as they are typically used to transport electrons.
In one aspect, the compound used in ETL contains at least one of the following groups in the molecule:




wherein R101 is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. Ar1 to Ara has the similar definition as Ar's mentioned above. k is an integer from 1 to 20. X101 to X108 is selected from C (including CH) or N.

In another aspect, the metal complexes used in ETL contains, but is not limited to, the following general formula:




wherein (O—N) or (N—N) is a bidentate ligand, having metal coordinated to atoms O, N or N, N; L101 is another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal.

In any above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms can be partially or fully deuterated. Thus, any specifically listed substituent, such as, without limitation, methyl, phenyl, pyridyl, etc. encompasses undeuterated, partially deuterated, and fully deuterated versions thereof. Similarly, classes of substituents such as, without limitation, alkyl, aryl, cycloalkyl, heteroaryl, etc. also encompass undeuterated, partially deuterated, and fully deuterated versions thereof.
In addition to and/or in combination with the materials disclosed herein, many hole injection materials, hole transporting materials, host materials, dopant materials, exiton/hole blocking layer materials, electron transporting and electron injecting materials may be used in an OLED. Non-limiting examples of the materials that may be used in an OLED in combination with materials disclosed herein are listed in Table A below. Table A lists non-limiting classes of materials, non-limiting examples of compounds for each class, and references that disclose the materials.









TABLE A





MATERIAL
EXAMPLES OF MATERIAL
PUBLICATIONS















Hole injection materials









Phthalocyanine and porphyrin compounds




Appl. Phys. Lett.  69, 2160 (1996)


 


Starburst triarylamines




J. Lumin. 72-74,  985 (1997)


 


CFx Fluorohydrocarbon




Appl. Phys. Lett. 


polymer

78, 673 (2001)


 


Conducting polymers (e.g., PEDOT:PSS, polyaniline, polythiophene)




Synth. Met.  87, 171 (1997) WO2007002683


 


Phosphonic acid and  silane SAMs




US20030162053


 


Triarylamine or polythiophene  polymers with conductivity  dopants




EP1725079A1


 










 










 


Organic compounds  with conductive  inorganic compounds, such as molybdenum and  tungsten oxides 




US20050123751 SID Symposium Digest, 37,  923 (2006) WO2009018009 


 


n-type semiconducting organic complexes




US20020158242


 


Metal organometallic complexes




US20060240279


 


Cross-linkable  compounds




US20080220265


 


Polythiophene based polymers and  copolymers




WO 2011075644 EP2350216


 







Hole transporting materials









Triarylamines (e.g., TPD, α-NPD)




Appl. Phys. Lett.  51, 913 (1987)


 







US5061569


 







EP650955


 







J. Mater. Chem.  3, 319 (1993)


 







Appl. Phys. Lett.  90, 183503 (2007)


 







Appl. Phys. Lett. 90, 183503 (2007)


 


Triarylamine on spirofluorene core




Synth. Met. 91,  209 (1997)


 


Arylamine carbazole compounds




Adv. Mater. 6, 677 (1994), US20080124572 


 


Triarylamine with (di)benzothiophene/ (di)benzofuran




US20070278938, US20080106190 US20110163302


 


Indolocarbazoles




Synth. Met. 111,  421 (2000)


 


Isoindole compounds




Chem. Mater. 15,  3148 (2003)


 


Metal carbene complexes




US20080018221


 







Phosphorescent OLED host materials


Red hosts









Arylcarbazoles




Appl. Phys. Lett.  78, 1622 (2001)


 


Metal  8-hydroxyquinolates (e.g., Alq3, BAlq)




Nature 395, 151  (1998)


 







US20060202194


 







WO2005014551


 







WO2006072002


 


Metal phenoxybenzothiazole compounds




Appl. Phys. Lett.  90, 123509 (2007)


 


Conjugated oligomers  and polymers (e.g., polyfluorene)




Org. Electron. 1,  15 (2000)


 


Aromatic fused rings




WO2009066779,  WO2009066778, WO2009063833, US20090045731, US20090045730, WO2009008311, US20090008605, US20090009065


 


Zinc complexes




WO2010056066


 


Chrysene based compounds




WO2011086863


 







Green hosts









Arylcarbazoles




Appl. Phys. Lett.  78, 1622 (2001)


 







US20030175553


 







WO2001039234


 


Aryltriphenylene compounds




US20060280965


 







US20060280965


 







W02009021126


 


Poly-fused heteroaryl compounds




US20090309488  US20090302743 US20100012931


 


Donor acceptor type molecules




WO2008056746


 







WO2010107244


 


Aza-carbazole/DBT/ DBF




JP2008074939


 







US20100187984


 


Polymers (e.g., PVK)




Appl. Phys. Lett.  77, 2280 (2000)


 


Spirofluorene  compounds




WO2004093207


 


Metal phenoxybenzooxazole compounds




W02005089025


 







WO2006132173


 







JP200511610


 


Spirofluorene-carbazole compounds




JP2007254297


 







JP2007254297


 


Indolocarbazoles




WO2007063796


 







WO2007063754


 


5-member ring electron deficient heterocycles (e.g., triazole,  oxadiazole)




J. Appl. Phys.  90, 5048 (2001)


 







WO2004107822


 


Tetraphenylene complexes




US20050112407


 


Metal phenoxypyridine compounds




WO2005030900


 


Metal coordination complexes (e.g., Zn, Al with N{circumflex over ( )}N ligands) 




US20040137268,  US20040137267


 







Blue hosts









Arylcarbazoles




Appl. Phys. Lett,  82, 2422 (2003)


 







US20070190359


 


Dibenzothiophene/ Dibenzofuran-carbazole compounds




WO2006114966, US20090167162


 







US20090167162


 







WO2009086028


 







US20090030202, US20090017330


 







US20100084966


 


Silicon aryl compounds




US20050238919


 







WO2009003898


 


Silicon/Germanium  aryl compounds




EP2034538A


 


Aryl benzoyl ester




WO2006100298


 


Carbazole linked by  non-conjugated groups




US20040115476


 


Aza-carbazoles




US20060121308


 


High triplet metal organometallic complex




US7154114


 







Phosphorescent dopants


Red dopants









Heavy metal porphyrins (e.g., PtOEP)




Nature 395,  151 (1998)


 


Iridium(III)  organometallic  complexes




Appl. Phys. Lett.  78, 1622 (2001)


 







US20030072964


 







US20030072964


 







US20060202194


 







US20060202194


 







US20070087321


 







US20080261076 US20100090591


 







US20070087321


 







Adv. Mater.  19, 739 (2007)


 







WO2009100991


 







WO2008101842


 







US7232618


 


Platinum(II) organometallic  complexes




WO2003040257


 







US20070103060


 


Osmium(III) complexes




Chem. Mater.  17, 3532 (2005)


 


Ruthenium(II)  complexes




Adv. Mater.  17, 1059 (2005)


 


Rhenium (I), (II),  and (III) complexes




US20050244673


 







Green dopants









Iridium(III)  organometallic complexes




Inorg. Chem.  40, 1704 (2001)


 







US20020034656


 







US7332232


 







US20090108737


 







WO2010028151


 







EP1841834B


 







US20060127696


 







US20090039776


 







US6921915


 







US20100244004


 







US6687266


 







Chem. Mater. 16, 2480 (2004)


 







US20070190359


 







US 20060008670 JP2007123392


 







WO2010086089, WO2011044988


 







Adv. Mater.  16, 2003 (2004)


 







Angew. Chem. Int.  Ed. 2006, 45, 7800


 







WO2009050290


 







US20090165846


 







US20080015355


 







US20010015432


 







US20100295032


 


Monomer for  polymeric metal organometallic compounds




US7250226,  US7396598


 


Pt(II) organometallic complexes, including polydentated ligands




Appl. Phys. Lett.  86, 153505 (2005)


 







Appl. Phys. Lett.  86, 153505 (2005)


 







Chem. Lett. 34,  592 (2005)


 







WO2002015645


 







US20060263635


 







US20060182992 US20070103060


 


Cu complexes




WO2009000673


 







US20070111026


 


Gold complexes




Chem. Commun.  2906 (2005)


 


Rhenium(III)  complexes




Inorg. Chem. 42,  1248 (2003)


 


Osmium(II) complexes




US7279704


 


Deuterated  organometallic complexes




US20030138657


 


Organometallic  complexes with two or  more metal centers




US20030152802


 







US7090928


 







Blue dopants









Iridium(III)  organometallic complexes




WO2002002714


 







WO2006009024


 







US20060251923  US20110057559  US20110204333


 







US7393599, WO2006056418, US20050260441, WO2005019373 


 







US7534505


 







WO2011051404


 







US7445855


 







US20070190359, US20080297033 US20100148663


 







US7338722


 







US20020134984


 







Angew. Chem.  Int. Ed. 47, 4542 (2008)


 







Chem. Mater. 18,  5119 (2006)


 







Inorg. Chem. 46,  4308 (2007)


 







WO2005123873


 







W02005123873


 







WO2007004380


 







WO2006082742


 


Osmium(II) complexes




US7279704


 







Organometallics  23, 3745 (2004)


 


Gold complexes




Appl. Phys. Lett. 74, 1361  (1999)


 


Platinum(II) complexes




WO2006098120, WO2006103874


 


Pt tetradentate  complexes with at least one metal- carbene bond




US7655323


 







Exciton/hole blocking layer materials









Bathocuprine  compounds (e.g., BCP, BPhen)




Appl. Phys. Lett.  75, 4 (1999)


 







Appl. Phys. Lett.  79, 449 (2001)


 


Metal  8-hydroxyquinolates (e.g. BAlq)




Appl. Phys. Lett.  81, 162 (2002)


 


5-member ring electron deficient heterocycles  such as triazole,  oxadiazole, imidazole, benzoimidazole 




Appl. Phys. Lett.  81, 162 (2002)


 


Triphenylene  compounds




US20050025993


 


Fluorinated aromatic compounds




Appl. Phys. Lett.  79, 156 (2001)


 


Phenothiazine-S-oxide




WO2008132085


 


Silylated five- membered nitrogen, oxygen,  sulfur or phosphorus dibenzoheterocycles 




WO2010079051


 


Aza-carbazoles




US20060121308


 







Electron transporting materials









Anthracene- benzoimidazole compounds




WO2003060956


 







US20090179554


 


Aza triphenylene derivatives




US20090115316


 


Anthracene- benzothiazole compounds




Appl. Phys. Lett.  89, 063504 (2006)


 


Metal  8-hydroxyquinolates (e.g., Alq3, Zrq4)




Appl. Phys. Lett.  51, 913 (1987)  US7230107


 


Metal hydroxybenzoquinolates




Chem. Lett. 5,  905 (1993)


 


Bathocuprine  compounds such as BCP, BPhen,  etc




Appl. Phys. Lett. 91,  263503 (2007)


 







Appl. Phys. Lett.  79, 449 (2001)


 


5-member ring electron deficient heterocycles (e.g.,triazole,  oxadiazole, imidazole, benzoimidazole)




Appl. Phys. Lett.  74, 865 (1999)


 







Appl. Phys. Lett.  55, 1489 (1989)


 







Jpn. J. Apply. Phys.  32, L917 (1993)


 


Silole compounds




Org. Electron. 4,  113 (2003)


 


Arylborane compounds




J. Am. Chem. Soc.  120, 9714 (1998)


 


Fluorinated aromatic compounds




J. Am. Chem. Soc.  122, 1832 (2000)


 


Fullerene (e.g., C60)




US20090101870


 


Triazine complexes




US20040036077


 


Zn (N{circumflex over ( )}N) complexes




US6528187









EXPERIMENTAL
A nitrogen substitution in the benzimidazole phenanthridine ligand system is shown to have a desirably strong blue-shifting effect, by calculation and comparison to analogous structures, such as Iridium tris pyridyl-pyridine.
DFT calculations are shown in Table B below. DFT calculations were performed using the B3LYP/cep-31g/THF functional, basis set and solvent polarization, respectively.
The blue-shifting effect of the uncoordinated nitrogen is clearly shown in density functional theory (DFT) calculations, comparing Compounds 1, 7, 315, and 316 to Comparative Example 1, shown in Table B. Compounds 1, 7, 315, and 316 have calculated triplet energies in the range of 460-470 nm, while the triplet of Comparative Example 1 is calculated to be 493 nm. Experimental data for Comparative Example 1 is shown in FIG. 3. The highest energy peak emission for Comparative Example 1 in room temperature and 77K 2-methyltetrahydrofuran solvent is 494 and 487 nm, matching up well with the calculated value.
The uncoordinated nitrogen of the benzimidazole-azaphenanthridine ligand may be susceptible to being protonated in the excited state. Although not wishing to be bound by any particular theory, protonation of the uncoordinated nitrogen is believed to be an irreversible degradation event in an OLED device, leading to anionic and cationic degradation species.
A demonstrated herein, the benzimidazole-azaphenanthridine ligand provides a useful scaffold where a substituent on the ligand, such as aryl, can be used to sterically block the potentially reactive site of the ligand without lowering the triplet energy.
It can be seen in a space filling model of Compound 315, calculated by density functional theory (DFT), and shown in FIG. 4, that an aryl substituent sterically shields the uncoordinated nitrogen from close contact of a neighboring intra or intermolecular proton atom. The un-substituted Compound 1 has an unprotected nitrogen that may be susceptible to being protonated by any neighboring molecule in the solid state. Therefore a site blocking substituent may be a desirable feature for improving the stability. Aryl substitution is one example of a desired site blocking substitution. Furthermore, as the aryl substitution at this site necessarily twists out of the plane of the ligand, there is a minimal effect on the triplet energy of the complex.
Compounds 1, 7, 315, and 316 are compared to Comparative Examples 2 and 3 in order to demonstrate how the exemplary benzimidazole modification provides desirable features compared to unsubstituted imidazole. DFT calculations for Comparative Examples 2 and 3, the facial (fac) and meridional (mer) isomers of tris iridium imidazole aza-phenanthridine complexes, show triplet energies of 447 and 448 nm. Furthermore, Comparative Example 3 has been synthesized and the 77K solution emission spectrum is shown in FIG. 5. The highest energy peak emission for Comparative Example 3 is 431 nm. The complex was found to be nonemissive in room temperature solution. Therefore, while Comparative Examples 2 and 3 have deep blue emission, they are actually too high in energy to be supported by conventional host materials that typically contain carbazole, dibenzofuran and dibenzothiophene moieties, due to triplet quenching. Therefore the exemplary benzimidazole modification can red shift the emission energy into a desirable range where conventional OLED materials can be used for the fabrication of high efficiency and stable devices.







TABLE B







(where not explicitly stated, all complexes are facial (fac) isomers):
















HOMO
LUMO
Gap
Dipole
S1THF
T1THF



Structure
(eV)
(ev)
(ev)
(Debye)
(nm)
(nm)





Compound 1




−5.70
−1.86
−3.84
11.02
413
469


 


Compound 7




−5.63
−1.82
−3.81
 9.25
414
471


 


Compound 315




−5.65
−1.88
−3.78
10.94
421
474


 


Compound  316




−5.66
−1.86
−3.79
12.21
417
472


 


Comparative Example 1




−5.14
−1.62
−3.52
 7.01
451
493


 


Comparative Example 2




−5.56
−1.52
−4.04
10.35
411
447


 


Comparative Example 3




−5.57
−1.50
−4.08
 6.03
390
448









Representative Photophysical Properties (Compound 7)

The photophysical properties of Compound 7 are described as a representative example of this family of blue emitters. The spectrum of Compound 7 in room temperature and 77K 2-methyltetrahydrofuran solvent and solid state polymethylmethacrylate (PMMA) matrix are shown in FIG. 6. In 2-methyltetrahydrofuran solvent, Compound 7 has a peak emission at 459 nm and 463 nm, respectively, with well-defined vibronic structure. The excited state lifetime at 77K was measured to be 2.9 microseconds, which is shorter than the lifetime of Iridium tris-phenylpyridine [Ir(ppy)3=4 microseconds]. The photoluminescent quantum yield (PLQY) was measured for Compound 7 doped in a solid state PMMA matrix drop cast at 1 wt % on a quartz substrate. The PLQY was measured to be 100% efficient with a corresponding excited state lifetime of 2.3 microseconds. These results demonstrate that this family of compounds has excellent intrinsic photophysical properties as blue phosphorescent emitters with high efficiency and short excited state lifetime.
Device Data
OLED devices were prepared using Compound 307 and Compound 308 as emitters.
LG101 was used at HIL







Device 1=ITO (800 Å)/LG101 (100 Å)/HTL 1 (250 Å)/Host1 (50 Å)/Host 1:Host 2:Compound 307 (40:50:10%, 300 Å)/EBL 1 (50 Å)AlQ3 (300 Å)/LiQ/Al
Device 2=ITO (800 Å)/LG101 (100 Å)/HTL 1 (250 Å)/Host1 (50 Å)/Host 1:Host 2:Compound 308 (40:50:10%, 300 Å)/EBL 1 (50 Å)AlQ3 (300 Å)/LiQ/Al














At 1000 nits
At 20 mA/cm2














1931 CIE
Voltage
LE
EQE
PE
LT80

















x
y
λ max
FWHM
(V)
[cd/A]
[%]
[lm/W]
[h]




















Device 1
0.165
0.341
472
58
4.3
12.0
5.9
8.8
3.1


Device 2
0.163
0.319
490
71
5.2
7.3
3.7
4.4
0.6









Synthesis of Exemplary Ligands and Complexes













Synthesis of Compounds 306-308
(See FIG. 7 for exemplary synthetic scheme)
Synthesis of 1,2-diethyl-4,5-diiodobenzene (1)




1,2-diethyl benzene (4.0 grams, 29.8 mmol) was placed in a flask. Acetic acid (20 mL), water (4 mL) and sulfuric acid (0.6 mL) were added. Iodine (6.81 grams (26.8 mmol) and periodic acid (2.69 grams, 11.92 mmol) were then added and the reaction was stirred in an oil bath at 75° C. for 18 hours. The mixture was then poured into aqueous sodium bisulfite and the product was extracted with DCM. The organic layer was washed with aqueous sodium bicarbonate solution and evaporated to a yellow oil (10.1 grams, 88%).
Synthesis of 1,2-diisobutylbenzene (2)




Pd2(dba)3 (1.33 g, 1.45 mmol), 1,2-diiodobenzene (12 g, 36.4 mmol), isobutylboronic acid (14.83 g, 145 mmol), S-Phos (2.39 g, 5.82 mmol) and K3PO4 (38.6 g, 182 mmol) were refluxed in degassed toluene (350 mL) and water (175 mL) overnight. The mixture was filtered through celite and washed with heptanes. The layers were separated and the organic fractions were evaporated to a dark red oil. Heptane was added to this oil and the mixture was again filtered and evaporated. The crude material was passed through a silica gel plug, eluting with 1:1 DCM/heptanes, ultimately yielding 6.54 g of product as an oil, 94%.
Synthesis of 1,2-diiodo-4,5-diisobutylbenzene (3)




A mixture of 1,2-diisobutylbenzene 2 (6.5 g, 34.2 mmol), diiodine (8.23 g, 32.4 mmol) and orthoperiodic acid (3.09 g, 13.7 mmol) in acetic acid (30 mL), water (20 mL) and conc. sulfuric acid (0.90 mL) was stirred at 70° C. for 1 day. The mixture was poured into aqueous sodium thiosulfate and extracted with DCM. The organic layer was washed with sodium bicarbonate, then water, and solvent was removed under vacuum. The crude oil was passed through a silica gel plug and eluted with heptanes, yielding 10.5 g of yellow oil, 70%.
Synthesis of 2-methylbenzo[h][1,6]naphthyridin-5-amine (4)




A 500 ml, flask was charged with 2-chloro-6-methylnicotinonitrile (6.0 grams, 39.3 mmol), 2-aminophenylboronic acid pinacol ester (10.34 grams, 47.2 mmol), Palladium dppf-dichloride dichloromethane adduct (1.44 grams, 1.97 mmol) and potassium carbonate (5.43 grams, 39.3 mmol). Dioxane (120 mL) and water (24 mL) were then added. This mixture was stirred at reflux for 18 hours. The crude mix was then diluted with ethyl acetate and filtered through celite. The filtrate was evaporated and chromatographed to give 7.6 grams (92%) of product.
Synthesis of 11,12-diethyl-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (5)




A 250 mL flask was charged with 4 (3.0 grams, 14.3 mmol), 1 (6.64 grams, 17.2 mmol), copper iodide (0.41 grams, 2.15 mmmol), N,N′-dimethylethylenediamine (0.46 mL, 4.3 mmol) and cesium carbonate (9.34 grams, 28.7 mmol). This was evacuated and backfilled with nitrogen. N-methyl-2-pyrrolidinone (100 mL) was then added and this was stirred in an oil bath at 150° C. for 20 hours. The mix was then filtered through celite and the cake was washed with ethyl acetate. The filtrate was washed with brine and water. Column chromatography of the organic extracts yielded 2.4 grams (49.3%) of product as a beige solid.
Synthesis of Compound 306




Ligand 5 (1.8 grams, 5.30 mmol) was placed into a Schlenk tube. Ir(acac)3 (0.52 grams, 1.06 mmol) and pentadecane (3 mL) were added. This was evacuated and backfilled with nitrogen. The reaction was stirred in a sand bath at 300° C. for 4 days. The mix was diluted with DCM and chromatographed using MeOH/DCM. The solid was purified by repeated precipitation from DCM using MeOH to yield 0.4 grams (31%) of Compound 306 as a yellow solid.
Synthesis of 11,12-diisobutyl-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (7)




4 (2.00 g, 9.56 mmol) and cesium carbonate (6.23 g, 19.12 mmol) were combined in a 3-neck flask, which was flushed with nitrogen. 3 (4.23 g, 9.56 mmol) was added, followed by a solution of copper(I) iodide (0.273 g, 1.434 mmol) and N1,N2-dimethylethane-1,2-diamine (0.309 ml, 2.87 mmol) in dry N-methyl-2-pyrrolidinone (100 ml). The mixture was heated at 150° C. overnight. The reaction mixture was diluted with ethyl acetate and filtered through celite. Solvent was removed under vacuum and the residue was coated on celite and purified by column chromatography to yield 1.33 g of beige/orange solid that was recrystallized from MeCN to give a pale yellow fluff, 1.26 g (33%).
Synthesis of Compound 307




7 (1.25 g, 3.16 mmol) and Ir(acac)3 (0.30 g, 0.613 mmol) were combined in pentadecane (3 ml). The mixture was degassed then heated at reflux under nitrogen for 2 days. The mixture was coated on celite and the product was purified by silica gel column chromatography, yielding 450 mg of yellow solids that were sonicated in  ̃20 mL heptanes, yielding 344 mg of light yellow solid Compound 307.
Synthesis of 11,12-difluoro-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (9)




4 (2.53 g, 12.09 mmol), 1,2-dibromo-4,5-difluorobenzene (3.62 g, 13.30 mmol), XantPhos (0.350 g, 0.605 mmol), diacetoxypalladium (0.136 g, 0.605 mmol) and Cs2CO3 (15.76 g, 48.4 mmol) were combined in a flask, flushed with nitrogen, then degassed toluene (48.4 ml) was added and the mixture was heated at reflux for three days. Solvent was removed under vacuum and the residue was suspended in 100 mL water. Solids were filtered off and washed with Et2O and dried under vacuum. Trituration of the solids in 20 mL DCM yielded 9 as a light solid, 2.85 g (74%).
Synthesis of Compound 308




9 (2.409 g, 7.54 mmol) and Ir(acac)3 (0.739 g, 1.510 mmol) were combined in pentadecane (3 ml), the mixture was degassed and refluxed for 5 days. The mixture was cooled to room temperature, dissolved in  ̃400 mL DCM (some dark precipitates still there), and passed through a deactivated neutral alumina column, flushing with DCM. Excess ligand was removed from the isolated yellow solid was removed in a sublimator and the residue was triturated in DCM to yield 0.41 g of Compound 308.
Synthesis of Compounds 110, 309, and 310
(See FIG. 8 for exemplary synthetic scheme)
Synthesis of 4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (11)




A mixture of 2-bromo-4-chloroaniline (10 g, 48.4 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (14.76 g, 58.1 mmol), potassium acetate (14.26 g, 145 mmol), and (dppf)PdCl2(CH2Cl2) (5%) was refluxed overnight in dioxane (240 mL). The mixture was diluted with EtOAc and filtered through celite. After evaporation, the crude material was chromatographed on silica gel to yield 8 g of 11 as a pale yellow solid (65%).
Synthesis of 9-chloro-2-methylbenzo[h][1,6]naphthyridin-5-amine (12)




A mixture of 2-chloro-6-methylnicotinonitrile (4 g, 26.2 mmol), 11 (7.31 g, 28.8 mmol), (dppf)PdCl2(CH2Cl2) (1.07 g, 1.31 mmol), and potassium carbonate (3.62 g, 26.2 mmol) was refluxed in dioxane (150 mL) and water (30 mL) overnight. The mixture was cooled to RT, diluted with EtOAc and filtered through celite. After separation and drying of the organic layer the material was chromatographed on silica gel to yield 6.55 g of material that was triturated in ether and heptanes to yield 5.24 g of 12 (82%).
Synthesis of 6-chloro-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (13)




A mixture of Cs2CO3 (13.90 g, 42.7 mmol), 12 (5.2 g, 21.3 mmol), 1,2-diiodobenzene (3.07 mL, 7.74 g, 23.5 mmol), CuI (0.610 g, 3.20 mmol), and N,N′-dimethylethane-1,2-diamine (0.69 mL, 6.40 mmol) was stirred at 150° C. in NMP (200 mL) for 20 hours. The cooled reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, concentrated and chromatographed using silica gel to give 2.9 g of 13 as a beige solid, 43%.
Synthesis of 6-(2,6-dimethylphenyl)-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (14)




A 250 mL flask was charged with 13 (1.8 grams, 5.66 mmol), 2,6-dimethyphenylboronic acid (1.27 grams, 8.5 mmol), Pd2(dba)3, (0.119 grams, 0.142 mmol), S-Phos (0.27 grams, 0.566 mmol) and potassium phosphate (3.61 grams, 16.99 mmol). This was diluted with dioxane (50 mL) and water (10 mL) and refluxed for 24 hours. The crude was diluted with DCM and filtered through celite. The filtrate was washed with brine and concentrated. Column gave 1.83 grams (83%) of 14.
Synthesis of Compound 110




14 (1.6 grams, 4.13 mmol), Ir(acac)3 (0.404 grams, 0.826 mmol) and pentadecane (3 mL) were placed in a Schlenk tube. This was stirred at 300° C. for 3 days. The product was chromatographed on silica gel and triturated in 1:1 DCM-heptane to give 0.4 grams (36%) of Compound 110.
Synthesis of 3-methyl-6-(2,4,6-triisopropylphenyl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (16)




13 (1.89 g, 5.95 mmol), (2,4,6-triisopropylphenyl)boronic acid (2.95 g, 11.90 mmol) and potassium phosphate monohydrate (4.11 g, 17.84 mmol) were combined in a Schlenk tube under nitrogen. Separately, a flask containing Pd2(dba)3 (0.109 g, 0.119 mmol) and X-Phos (0.227 g, 0.476 mmol) was purged with nitrogen, then nitrogen-sparged 5:1 dioxane/water (60 ml) was added and heated until the solution turns orange. The catalyst solution was added to the solid reagents and the mixture was refluxed overnight. The mixture was partitioned between water/brine and DCM. The organics were washed with brine and dried and purification of 16 was performed by silica gel chromatography, yielding a yellow-tinged solid, 2.11 g (73%).
Synthesis of Compound 309




Ligand 16 (1.974 g, 4.07 mmol) and Ir(acac)3 (0.398 g, 0.813 mmol) were combined in pentadecane (3 ml), then heated at reflux under nitrogen for 5 days. Purification of the crude mixture by silica gel chromatography yielded 0.81 g of Compound 9.
Synthesis of 6-chloro-11,12-diisobutyl-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (18)




A mixture of 12 (4 g, 16.4 mmol), 3 (7.26 g, 16.4 mmol), CuI (0.47 g, 2.46 mmol), N1,N2-dimethylethane-1,2-diamine (0.53 mL, 4.92 mmol), Cs2CO3 (10.7 g, 32.8 mmol) was stirred in NMP at 150° C. overnight. The mixture was diluted with EtOAc and filtered through celite. The filtrate was washed with brine then water, and the organic layer was chromatographed on silica gel columns to yield 2.87 g of 18 as a pale yellow solid, 41%.
Synthesis of 6-(2,6-dimethylphenyl)-11,12-diisobutyl-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (19)




18 (1.383 g, 3.22 mmol), (2,6-dimethylphenyl)boronic acid (0.627 g, 4.18 mmol) and potassium phosphate monohydrate (2.222 g, 9.65 mmol) were combined in a Schlenk tube under nitrogen. Separately Pd2(dba)3 (0.059 g, 0.064 mmol) and X-Phos (0.123 g, 0.257 mmol) were heated in 5:1 dioxane/water (30 ml) until orange. The catalyst solution was added to the solid reactants and refluxed for 4 hours. After partitioning between brine/water/DCM the aqueous layer was extracted three times with DCM, the combined organic layers were dried and coated on celite. The product was purified by silica gel chromatography, yielding a solid that was recrystallized from MeCN to yield 1.3 g of light yellow 19.
Synthesis of Compound 310




19 (1.32 g, 2.64 mmol) and Ir(acac)3 (0.25 g, 0.511 mmol) were combined in pentadecane (3 ml). The mixture was degassed then heated at reflux for 3 days. The mixture was coated on celite and purified by column chromatography to yield a solid that was triturated in MeOH, yielding 312 mg of Compound 310 as a pale yellow powder (36%).
Synthesis of Compound 311
(See FIG. 9 for exemplary synthetic scheme)
Synthesis of 8-chloro-2-methylbenzo[h][1,6]naphthyridin-5-amine (21)




A mixture of 2-bromo-5-chloroaniline (9.66 g, 46.8 mmol), PdCl2(dppf)DCM (1.124 g, 1.376 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (13.40 g, 52.8 mmol), and potassium acetate (9.01 g, 92 mmol) was dissolved in dioxane (70 ml) and stirred at reflux for 5 hours. After cooling to room temperature, 2-chloro-6-methylnicotinonitrile (7 g, 45.9 mmol) and potassium carbonate (6.34 g, 45.9 mmol) were added followed by degassed dioxane (30 ml) and water (20 ml) and the mixture was brought to reflux overnight. Solvents were removed under vacuum and the residual solids were triturated in 20 mL of diethyl ether and the solids were washed with water and more ether. The solids were dissolved in 10% MeOH/DCM and washed with brine/1M NaOH. Evaporation of the organic layer yielded 21 as a grey product, 64%.
Synthesis of 7-chloro-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (22)




A mixture of 21 (6 g, 24.62 mmol), copper(I) iodide (0.703 g, 3.69 mmol), N1,N2-dimethylethane-1,2-diamine (0.795 ml, 7.39 mmol), and cesium carbonate (16.04 g, 49.2 mmol) was vacuumed and back-filled with nitrogen several times and 1,2-diiodobenzene (3.54 ml, 27.1 mmol) and NMP (75 ml) were added to the flask. The reaction was heated at 150° C. overnight, quenched with water and the precipitated solids were filtered and washed with water. The solid was washed with DCM/1 M NaOH (aq) and brine. The organic fraction was evaporated and washed with diethyl ether to afford greyish 22, 61%

Synthesis of 7-(2,6-dimethylphenyl)-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (23)




A mixture of 22 (4.8 g, 15.11 mmol), (2,6-dimethylphenyl)boronic acid (2.72 g, 18.13 mmol), S-Phos Pd G2 catalyst (0.327 g, 0.453 mmol), S-Phos (0.186 g, 0.453 mmol), and potassium carbonate (2.088 g, 15.11 mmol) was vacuumed and back-filled with nitrogen several times. Dioxane (60 ml) and water (15 ml) were added and the mixture was refluxed for 3 hours. Solvents were removed under vacuum and the residue was dissolved in DCM and washed with brine/1 M KOH (aq). The organic layer was purified by silica gel chromatography and washed with diethyl ether to yield 23, 85%.
Synthesis of Compound 311




Ligand 23 (1.4 g) and Ir(acac)3 (0.354 g) were combined in a Schlenk tube and degassed, then heated to 295° C. in a sand bath for 3 days. The cooled reaction mixture was coated on celite using DCM and purified by column chromatography on silica gel and neutral alumina to afford Compound 311, 16%.
Synthesis of Compound 4
(See FIG. 10 for exemplary synthetic scheme)
Synthesis of 2-chloro-6-(2,6-dimethylphenyl)nicotinonitrile (25)




A 1 L flask was charged with 2,6-dichloronicotinonitrile (10 grams, 57.8 mmol), 2,6-dimethylphenylboronic acid (8.67 grams, 57.8 mmol), potassium carbonate (8.0 grams, 57.8 mmol) and Pd(dppf)Cl2 DCM adduct (1.42 grams, 1.73 mmol). This was diluted with dioxane (300 mL) and water (60 mL). The mix was stirred at reflux for 18 hours. This was diluted with ethyl acetate and brine. The organic layer was concentrated and chromatographed on silica gel to give 10.6 grams of 25.
Synthesis of 2-(2,6-dimethylphenyl)benzo[h][1,6]naphthyridin-5-amine (26)




A 1 L flask was charged with 25 (10.5 grams, 43.3 mmol), 2-aminophenylboronic acid pinacol ester (9.48 grams, 43.3 mmol), Pd(dppf)Cl2 DCM adduct (1.77 grams, 2.16 mmol) and potassium carbonate (5.98 grams, 43.3 mmol). The mix was diluted with dioxane (300 mL) and water (60 mL) and this was stirred at reflux for 18 hours. The mix was cooled and diluted with DCM. This was filtered through celite. The fitrate was washed with brine and concentrated. Chromatography on silica gel gave 5.36 grams (41%) of 26.
Synthesis of 3-(2,6-dimethylphenyl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (27)




A 250 mL flask was charged with 26 (5.3 grams, 17.7 mmol), 1,2-diiodobenzene (5.84 grams, 17.7 mmol), copper iodide (0.51 grams, 2.66 mmol), N,N′-dimethylethylenediamine (0.57 mL, 5.31 mmol) and cesium carbonate (11.54 grams, 35.4 mmol). This was diluted with N-methyl pyrrolidinone (100 mL). The reaction was stirred at 150° C. for 20 hours. The crude product was diluted with DCM and filtered through celite. The filtrate was washed with water and concentrated and residual NMP was removed by kugelrohr. Silica gel chromatography yielded 4.4 grams (67%) of 27.
Synthesis of Compound 4




Ligand 27 (3.0 grams, 8.03 mmol), Ir(acac)3 (0.787 grams, 1.6 mmol) and pentadecane (4.5 mL) were all placed in a 50 mL Schlenk tube. The flask was evacuated and backfilled with nitrogen. The mix was stirred in a sand bath at 295° C. for 4 days. The crude material was diluted with DCM and chromatographed on a silica gel column to give 610 mg of pure Compound 4.
Synthesis of Compound 7
(See FIG. 11 for exemplary synthetic scheme)
Synthesis of 10-methylbenzo[h][1,6]naphthyridin-5-amine (29)




A mixture of 2-bromo-3-methylaniline (5.41 ml, 43.3 mmol), PdCl2(dppf)DCM (0.884 g, 1.083 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15.27 ml, 87 mmol), and CyJohnPhos (0.759 g, 2.165 mmol) in dioxane (65 ml) was refluxed for 5 hours. The reaction mixture was cooled to room temperature and 2-chloronicotinonitrile (5 g, 36.1 mmol) and potassium carbonate (4.99 g, 36.1 mmol) were added to the flask. Degassed dioxane (20 ml) and water (17 ml) were added to the solution and refluxed was continued overnight. Solvents were removed and the residue was dissolved in 10% MeOH/DCM and washed with brine/KOH(aq). The organic layer evaporated and re-dissolved in THF (50 mL) and cooled in an ice bath. Sodium hydride (1.155 g, 28.9 mmol) was added and stirred at room temperature for 15 minutes. The reaction was quenched with water and extracted with DCM/brine. The resulting product was evaporated and triturated in diethyl ether/hexane ( ̃1:5) to afford brown 29 (45%).
Synthesis of 5-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (30)




A mixture of 29 (3.4 g, 16.25 mmol), copper(I) iodide (0.464 g, 2.437 mmol), N1,N2-dimethylethane-1,2-diamine (0.525 ml, 4.87 mmol), and cesium carbonate (10.59 g, 32.5 mmol) was vacuumed and back-filled with nitrogen several times and 1,2-diiodobenzene (2.336 ml, 17.87 mmol) and NMP (45 ml) were added to the solution. The reaction was heated at 150° C. for 3 hours. The reaction was diluted with water and precipitated solids were collected by filtration and washed with water. The solid was purified by silica gel chromatography and triturated in diethyl ether to afford light brick-colored solid (48%).

Synthesis of Compound 7




Ligand 30 (1.5 g) and Ir(acac)3 (0.518 g) were combined in pentadecane in a Schlenk tube and degassed, then heated to 285° C. in a sand bath for 3 days. The product was purified by silica gel chromatography to afford Compound 7 (11%).
Synthesis of Compounds 312-314
(See FIG. 12 for an exemplary synthetic scheme)
Synthesis of 10-chloro-2-methylbenzo[h][1,6]naphthyridin-5-amine (32)




A mixture of Pd(CH3CN)2Cl2 (0.136 g, 0.524 mmol) and CyJohnPhos (0.368 g, 1.049 mmol) was dissolved in dioxane (60 ml). 3-chloro-2-iodoaniline (6.98 g, 27.5 mmol), triethylamine (10.96 ml, 79 mmol), and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (7.99 ml, 55.1 mmol) were added to the solution in sequence via syringe. The reaction was reflux for 3 hours. The mixture was cooled to room temperature and solid 2-chloro-6-methylnicotinonitrile (4 g, 26.2 mmol), S-Phos Pd G2 (0.378 g, 0.524 mmol), S-Phos (0.215 g, 0.524 mmol), and potassium carbonate (7.25 g, 52.4 mmol) were added to the reaction mixture dioxane (15 ml) and water (15 ml) and the reaction was heated to 80° C. overnight. Solvents were removed under vacuum and the crude residue was dissolved in DCM and washed with KOH(aq)/brine. After evaporation of the organic layer the solids were re-dissolved in THF (35 mL) and sodium hydride (1.573 g, 39.3 mmol) was added to the solution at 0° C. and stirred for 10 min. The reaction was quenched with water and extracted with DCM. Evaporation of the organic layer and trituration in 1:1 diethyl ether and hexane ( ̃1:1) yielded 32 as a yellow crystalline solid (46%).
Synthesis of 5-chloro-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (33)




A mixture of 32 (200 mg, 0.821 mmol), diacetoxypalladium (9.21 mg, 0.041 mmol), Xantphos (23.74 mg, 0.041 mmol), and cesium carbonate (1070 mg, 3.28 mmol) was vacuumed and back-filled with nitrogen several times and 1,2-diiodobenzene (0.118 ml, 0.903 mmol) and toluene (8 ml) were added. The reaction was reflux for 2 hours, cooled to room temperature and extracted with DCM. The organic layer was dried, evaporated and the solids were triturated with diethyl ether and used in the next step without further purification.
Synthesis of 5-(2,6-dimethylphenyl)-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (34)




A mixture of 33 (3.0 g, 9.44 mmol), (2,6-dimethylphenyl)boronic acid (2.83 g, 18.88 mmol), diacetoxypalladium (0.212 g, 0.944 mmol), triphenylphosphine oxide (0.525 g, 1.888 mmol), and cesium fluoride (3.59 g, 23.60 mmol) was vacuumed and back-filled with nitrogen several times. THF (60 ml) was added and the mixture was refluxed overnight. After cooling to room temperature the mixture was coated on celite and purified by silica gel chromatography and the product was triturated in hexane to yield 34 (50%).

Synthesis of Compound 312




Ligand 34 (1.5 g) and Ir(acac)3 (0.379 g) were combined in a Schlenk tube in pentadecane (2 mL), degassed and heated to 295° C. in a sand bath for 3 days. The mixture was dissolved in DCM, filtered, then purified by silica gel and neutral alumina chromatography to afford Compound 312 (5%).
Synthesis of 10-(3,5-dimethylphenyl)-2-methylbenzo[h][1,6]naphthyridin-5-amine (36)




A mixture of 32 (2 g, 8.21 mmol), (3,5-dimethylphenyl)boronic acid (2.216 g, 14.77 mmol), S-Phos Pd G2 (0.237 g, 0.328 mmol), S-Phos (0.135 g, 0.328 mmol), and potassium carbonate (1.134 g, 8.21 mmol) was vacuumed and back-filled with nitrogen several times. Dioxane (35 ml) and water (7 ml) were added and the mixture was refluxed overnight. After evaporation of the solvent the residue was dissolved in a small amount of MeOH and precipitated using water/brine. The solids formed were filtered, dried and used without further purification, quantitative yield.

Synthesis of 5-(3,5-dimethylphenyl)-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (37)




A mixture of 36 (2.57 g, 8.20 mmol), copper(I) iodide (0.234 g, 1.230 mmol), N1,N2-dimethylethane-1,2-diamine (0.265 ml, 2.460 mmol), and cesium carbonate (5.34 g, 16.40 mmol) was vacuumed and back-filled with nitrogen several times and 1,2-diiodobenzene (1.393 ml, 10.66 mmol) and NMP (35 ml) were added. The reaction was heated at 150° C. overnight and addition of water/brine formed precipitates that were filtered. The solid was dissolved in DCM, washed and washed with brine. 37 was isolated by silica gel chromatography and washed with diethyl ether to afford an off-white solid (1.36 g, 43% over two steps).

Synthesis of Compound 313




Ligand 37 (1 g) and Ir(acac)3 (0.253 g) were combined in pentadecane (2 mL) in a 23 mL parr bomb which was heated to 290° C. in a sand bath for 3 days. The product was triturated in DCM to afford Compound 313 (85%).
Synthesis of 10-(4-isobutylphenyl)-2-methylbenzo[h][1,6]naphthyridin-5-amine (39)




A mixture of 32 (360 mg, 1.477 mmol), (4-isobutylphenyl)boronic acid (473 mg, 2.66 mmol), S-Phos Pd G2 (42.6 mg, 0.059 mmol), S-Phos (24.26 mg, 0.059 mmol), and potassium carbonate (204 mg, 1.477 mmol) was vacuumed and back-filled with nitrogen several times. Dioxane (10 ml) and water (2 ml) were added and the mixture was refluxed overnight. Removal of solvent yielded a residue that was washed with water and dried and used in the next step without further purification.

Synthesis of 5-(4-isobutylphenyl)-3-methylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (40)




A mixture of 39 (504 mg, 1.476 mmol), copper(I) iodide (42.2 mg, 0.221 mmol), N1,N2-dimethylethane-1,2-diamine (0.048 ml, 0.443 mmol), and cesium carbonate (962 mg, 2.95 mmol) was vacuumed and back-filled with nitrogen several times and 1,2-diiodobenzene (0.289 ml, 2.214 mmol) and NMP (10 ml) were added. The reaction was heated at 150° C. overnight, then water was added to form precipitates which were filtered. This solid was dissolved in DCM and washed with brine. The organic layer was purified by column chromatography to yield 40 (32% over two steps).
Synthesis of Compound 314




Ligand 40 (180 mg) and Ir(acac)3 (42.4 mg) were combined in pentadecane (0.5 mL) in a 25 mL Schlenk tube, degassed, then heated to 290° C. for 2 days. The mixture was separated using neutral alumina chromatography and isolated Compound 314 (20%) was triturated in diethyl ether.
It is understood that the various embodiments described herein are by way of example only, and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without deviating from the spirit of the invention. The present invention as claimed may therefore include variations from the particular examples and preferred embodiments described herein, as will be apparent to one of skill in the art. It is understood that various theories as to why the invention works are not intended to be limiting.
The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

## Claims

1. A compound comprising a ligand LA of Formula I:



wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, ester, nitrile, and isonitrile;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to form a tridentate, tetradentate, pentadentate or hexadentate ligand.

2. The compound of claim 1, wherein the compound has the formula M(LA)m(LB)n, having the structure:



wherein LB is a different ligand from LA; and
wherein m is an integer from 1 to the maximum number of ligands that may be coordinated to the metal M; m+n is the maximum number of ligands that may be coordinated to the metal M.

3. The compound of claim 1, wherein M is selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu.

4. The compound of claim 1, wherein M is Ir.

5. The compound of claim 1, wherein the ligand LA has the structure of:



wherein R is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, and isonitrile.

6. The compound of claim 5, wherein R is selected from the group consisting of alkyl, cycloalkyl, silyl, aryl, heteroaryl, and combinations thereof.

7. A formulation comprising a compound comprising a ligand LA of Formula I:



wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, carboxylic acids, ester, nitrile, and isonitrile;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to form a tridentate, tetradentate, pentadentate or hexadentate ligand.

8. The compound of claim 1, wherein the compound has the structure:

9. The compound of claim 5, wherein the compound has the structure:

10. The compound of claim 1, wherein the ligand LA is selected from the group consisting of:

11. The compound of claim 10, wherein the compound is selected from the group consisting of Compound 1 through Compound 316;
wherein each Compound x has the formula Ir(LAi)3; and
wherein x=i; i is an integer from 1 to 316.

12. The compound of claim 1, wherein the compound has the formula Ir(LA)m(LB)3-m, having the structure:



wherein LB is a different ligand from LA;
wherein m is 1 or 2;
wherein LB is selected from the group consisting of:










wherein each X1 to X13 is independently selected from the group consisting of carbon and nitrogen;
wherein X is selected from the group consisting of BR′, NR′, PR′, O, S, Se, C═O, S═O, SO2, CR′R′′, SiR′R′′, and GeR′R′′;
wherein R′ and R′′ are optionally fused or joined to form a ring;
wherein each Ra, Rb, Rc, and Rd may represent from mono substitution to the possible maximum number of substitution, or no substitution;
wherein Ra, Rb, Rc, and Rd are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, carboxylic acids, ester, nitrile, and isonitrile; and
wherein when Ra, Rb, Rc, and Rd represent at least di substitution, each of the two adjacent Ra, two adjacent Rb, two adjacent Rc, and two adjacent Rd are optionally fused or joined to form a ring or form a multidentate ligand.

13. The compound of claim 12, wherein LB is selected from the group consisting of:

14. The compound of claim 10, wherein the compound is selected from the group consisting of Compound 317 through Compound 84,688;
wherein each Compound x has the formula Ir(LAi)(LBj)2;
wherein LBi is selected from the group consisting of:







































































































































































and wherein x=316j+i; i is an integer from 1 to 316, and j is an integer from 1 to 267.

15. The compound of claim 12, wherein the LB is chosen such that the HOMO energy in Ir(LB)3 is deeper than that in Ir(LA)3.

16. The compound of claim 1, wherein the compound is selected from the group consisting of:

17. A first device comprising a first organic light emitting device, the first organic light emitting device comprising:
an anode;
a cathode; and
an organic layer, disposed between the anode and the cathode, comprising a compound comprising a ligand LA of Formula I:




wherein R1 represents mono, or di-substitution, or no substitution;
wherein R2 and R3 each independently represent mono, di, tri, or tetra-substitution, or no substitution;
wherein any adjacent substitutions in R1, R2 and R3 are optionally linked together to form a ring;
wherein R1, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, and isonitrile;
wherein the ligand LA is coordinated to a metal M; and
wherein the ligand LA is optionally linked with other ligands to form a tridentate, tetradentate, pentadentate or hexadentate ligand.

18. The first device of claim 17, wherein the first device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel.

19. The first device of claim 17, wherein the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant.

20. The first device of claim 17, wherein the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.

21. The compound of claim 1, wherein the compound has a calculated triplet energy between 469 nm and 474 nm.